In this phase IIb trial, patients with Claudin 18.2-positive, HER2-negative advanced GC were randomized to receive zolbetuximab plus EOX (epirubicin, oxaliplatin, and capecitabine) versus EOX alone [71]. This evidence concerns the gene CLDN18 and gastric cancer.